Seroatlas · Human Serome Atlas

FATE1

Fetal and adult testis-expressed transcript protein

Also known as: CT43, FATE, FATE1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q969F0
Gene: FATE1
Ensembl: ENSG00000147378
Chromosome: X
Canonical length: 183 aa
Protein class: Predicted intracellular proteins, Predicted membrane proteins

OverviewNCBI Gene

This gene encodes a cancer-testis antigen that is highly expressed in hepatocellular carcinomas and other tumors and weakly expressed in normal tissues except testis. The protein is strongly expressed in spermatogonia, primary spermatocytes, and Sertoli cells in seminiferous tubules. This protein may have a role in the control of early testicular differentiation and cell proliferation. [provided by RefSeq, Jan 2010]

Canonical amino-acid sequenceUniProt

183 residues, UniProt reviewed canonical sequence.

>Q969F0|FATE1
     1  MAGGPPNTKA EMEMSLAEEL NHGRQGENQE HLVIAEMMEL GSRSRGASQK KQKLEQKAAG
    61  SASAKRVWNM TATRPKKMGS QLPKPRMLRE SGHGDAHLQE YAGNFQGIRF HYDRNPGTDA
   121  VAQTSLEEFN VLEMEVMRRQ LYAVNRRLRA LEEQGATWRH RETLIIAVLV SASIANLWLW
   181  MNQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FATE1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Other membrane
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.63
Highest tissue expression: 233 nTPM

Expression across tissuesHPA

Tissue

testis: 233 nTPM
thymus: 2.1 nTPM
heart muscle: 1 nTPM
cerebral cortex: 0.8 nTPM
thyroid gland: 0.6 nTPM
pituitary gland: 0.5 nTPM

Single-cell type

sertoli cells: 312 nCPM
late spermatids: 97 nCPM
late primary spermatocytes: 29 nCPM
early spermatids: 25 nCPM
neuroendocrine cells: 15 nCPM
leydig cells: 7.9 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebral cortex: 1 nTPM
white matter: 0.7 nTPM
basal ganglia: 0.4 nTPM
hypothalamus: 0.2 nTPM
amygdala: 0.1 nTPM
hippocampal formation: 0.1 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.36
gnomAD pLI: 0.01
gnomAD missense Z: -0.34
DepMap mean gene effect: 0.01
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

Mff-like domain
Mitochondrial and peroxisomal fission factor Mff
Fetal and adult testis-expressed transcript protein

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of FATE1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FATE1 as an antibody target. Whether an autoantibody or antibody against FATE1 could matter depends on whether native FATE1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FATE1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label FATE1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...